Once considered obscure or opportunistic, invasive fungal infections are now surfacing with alarming frequency - and in ...

Researchers developed and used a novel blood test to diagnose and successfully treat a patient with a rare form of a severe ...

Most cases of nocardiosis start out as lung infections, in which pus-filled cavities, or abscesses containing the bacteria, form in the lungs. This can cause symptoms such as chest pain, a cough ...

Bowen’s disease causes reddish, sometimes brown, patches on sun-damaged skin, most often on your legs. You may also see the patches on your head, neck, palms of your hands, and soles of your feet.

(Photo by Saul Loeb / AFP) US President Donald Trump declared Thursday that the United States would sign a deal with Ukraine “very shortly” to gain access to its rare earths and other minerals. Last ...

When Maddie was nine years old, they were referred to the IU Undiagnosed Rare Disease Clinic, which opened at Riley Children’s Hospital in 2020. In a last ditch effort, they went through another ...

Today, the Governments of Canada and Nova Scotia signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest over $39 million over three years to improve access to new drugs for ...

This milestone is driving cutting-edge research aimed at developing the first treatment for AARS2 Deficiency, a potentially fatal rare genetic disease with no approved therapies currently on the ...

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition ... COVID-19 linked to higher risk for autoimmune diseases like alopecia, Crohn's New medication may treat ...

Lower doses of a common antibiotic can curb hair loss caused by a rare skin condition, a new study says. The antibiotic doxycycline is commonly used to treat lymphocytic scarring alopecia ...

a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks. Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017.

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the ...